| Nikolaos Zacharias, MD | |
|
1 Medical Center Dr, Vascular Surgery, Lebanon, NH 03756-1000 | |
| (603) 650-8677 | |
| Not Available |
| Full Name | Nikolaos Zacharias |
|---|---|
| Gender | Male |
| Speciality | Vascular Surgery |
| Experience | 22 Years |
| Location | 1 Medical Center Dr, Lebanon, New Hampshire |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023251717 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2086S0129X | Surgery - Vascular Surgery | 17544 (New Hampshire) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Partners Healthcare At Home - Home Care | Waltham, MA | Home health agency |
| Massachusetts General Hospital | Boston, MA | Hospital |
| Southern Nh Medical Center | Nashua, NH | Hospital |
| Brigham And Women's Hospital | Boston, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Foundation Medical Partners Inc | 9436140456 | 280 |
| Massachusetts General Physicians Organization Inc | 2466365820 | 3085 |
News Archive
Again, the Venza Group generated a positive impact on the lives of Georgia's foster and adoption families by sponsoring their 2nd Annual Charity Wine-Tasting Event. The crowd sipped and sampled in assistance of Supporting Adoption and Foster Families Together (SAFFT), a newly established organization that declares the following belief: BUILDING and MAINTAINING a supportive foundation for all caregivers improves the overall lives of children in care.
The drug was rejected in a 10-6 vote the first time it came before a Food and Drug Administration (FDA) advisory panel, in 2010, due to safety concerns. However when the medication returned for another review in February, the advisory committee gave it near-unanimous approval (20-2). Because the FDA often follows the advisory panel's advice, Qnexa is likely to get FDA approval, probably by mid-April.
The widespread adoption of the use of drug-releasing coronary artery stents into routine practice is associated with a decrease in the need for repeat procedures to unblock coronary arteries and also do not appear to increase the risk of death, compared to bare-metal stents, according to a study in the June 25 issue of JAMA, the Journal of the American Medical Association
Alex Dopico, MD, PhD, professor and Van Vleet Chair of Excellence in the Department of Pharmacology, Addiction Science, and Toxicology, and Anna Bukiya, PhD, associate professor in the Department of Pharmacology, Addiction Science, and Toxicology, have been awarded $2.4 million from the National Heart, Lung, and Blood Institute to explore how cholesterol interacts with the mechanisms that modulate blood vessel function in the brain.
The National Science Foundation recently funded research aimed at developing an engineered protein-lipid system that simultaneously delivers genes and drugs for the potential treatment of multi-drug resistant cancer cells. The dual-delivery system could also apply to diabetes and other conditions requiring a variety of therapeutic approaches.
› Verified 7 days ago
| Entity Name | Mary Hitchcock Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023092053 PECOS PAC ID: 4486561164 Enrollment ID: O20031126000258 |
News Archive
Again, the Venza Group generated a positive impact on the lives of Georgia's foster and adoption families by sponsoring their 2nd Annual Charity Wine-Tasting Event. The crowd sipped and sampled in assistance of Supporting Adoption and Foster Families Together (SAFFT), a newly established organization that declares the following belief: BUILDING and MAINTAINING a supportive foundation for all caregivers improves the overall lives of children in care.
The drug was rejected in a 10-6 vote the first time it came before a Food and Drug Administration (FDA) advisory panel, in 2010, due to safety concerns. However when the medication returned for another review in February, the advisory committee gave it near-unanimous approval (20-2). Because the FDA often follows the advisory panel's advice, Qnexa is likely to get FDA approval, probably by mid-April.
The widespread adoption of the use of drug-releasing coronary artery stents into routine practice is associated with a decrease in the need for repeat procedures to unblock coronary arteries and also do not appear to increase the risk of death, compared to bare-metal stents, according to a study in the June 25 issue of JAMA, the Journal of the American Medical Association
Alex Dopico, MD, PhD, professor and Van Vleet Chair of Excellence in the Department of Pharmacology, Addiction Science, and Toxicology, and Anna Bukiya, PhD, associate professor in the Department of Pharmacology, Addiction Science, and Toxicology, have been awarded $2.4 million from the National Heart, Lung, and Blood Institute to explore how cholesterol interacts with the mechanisms that modulate blood vessel function in the brain.
The National Science Foundation recently funded research aimed at developing an engineered protein-lipid system that simultaneously delivers genes and drugs for the potential treatment of multi-drug resistant cancer cells. The dual-delivery system could also apply to diabetes and other conditions requiring a variety of therapeutic approaches.
› Verified 7 days ago
| Entity Name | Foundation Medical Partners Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033162037 PECOS PAC ID: 9436140456 Enrollment ID: O20040519001048 |
News Archive
Again, the Venza Group generated a positive impact on the lives of Georgia's foster and adoption families by sponsoring their 2nd Annual Charity Wine-Tasting Event. The crowd sipped and sampled in assistance of Supporting Adoption and Foster Families Together (SAFFT), a newly established organization that declares the following belief: BUILDING and MAINTAINING a supportive foundation for all caregivers improves the overall lives of children in care.
The drug was rejected in a 10-6 vote the first time it came before a Food and Drug Administration (FDA) advisory panel, in 2010, due to safety concerns. However when the medication returned for another review in February, the advisory committee gave it near-unanimous approval (20-2). Because the FDA often follows the advisory panel's advice, Qnexa is likely to get FDA approval, probably by mid-April.
The widespread adoption of the use of drug-releasing coronary artery stents into routine practice is associated with a decrease in the need for repeat procedures to unblock coronary arteries and also do not appear to increase the risk of death, compared to bare-metal stents, according to a study in the June 25 issue of JAMA, the Journal of the American Medical Association
Alex Dopico, MD, PhD, professor and Van Vleet Chair of Excellence in the Department of Pharmacology, Addiction Science, and Toxicology, and Anna Bukiya, PhD, associate professor in the Department of Pharmacology, Addiction Science, and Toxicology, have been awarded $2.4 million from the National Heart, Lung, and Blood Institute to explore how cholesterol interacts with the mechanisms that modulate blood vessel function in the brain.
The National Science Foundation recently funded research aimed at developing an engineered protein-lipid system that simultaneously delivers genes and drugs for the potential treatment of multi-drug resistant cancer cells. The dual-delivery system could also apply to diabetes and other conditions requiring a variety of therapeutic approaches.
› Verified 7 days ago
| Entity Name | Dartmouth-hitchcock Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548210198 PECOS PAC ID: 4183537509 Enrollment ID: O20040809000442 |
News Archive
Again, the Venza Group generated a positive impact on the lives of Georgia's foster and adoption families by sponsoring their 2nd Annual Charity Wine-Tasting Event. The crowd sipped and sampled in assistance of Supporting Adoption and Foster Families Together (SAFFT), a newly established organization that declares the following belief: BUILDING and MAINTAINING a supportive foundation for all caregivers improves the overall lives of children in care.
The drug was rejected in a 10-6 vote the first time it came before a Food and Drug Administration (FDA) advisory panel, in 2010, due to safety concerns. However when the medication returned for another review in February, the advisory committee gave it near-unanimous approval (20-2). Because the FDA often follows the advisory panel's advice, Qnexa is likely to get FDA approval, probably by mid-April.
The widespread adoption of the use of drug-releasing coronary artery stents into routine practice is associated with a decrease in the need for repeat procedures to unblock coronary arteries and also do not appear to increase the risk of death, compared to bare-metal stents, according to a study in the June 25 issue of JAMA, the Journal of the American Medical Association
Alex Dopico, MD, PhD, professor and Van Vleet Chair of Excellence in the Department of Pharmacology, Addiction Science, and Toxicology, and Anna Bukiya, PhD, associate professor in the Department of Pharmacology, Addiction Science, and Toxicology, have been awarded $2.4 million from the National Heart, Lung, and Blood Institute to explore how cholesterol interacts with the mechanisms that modulate blood vessel function in the brain.
The National Science Foundation recently funded research aimed at developing an engineered protein-lipid system that simultaneously delivers genes and drugs for the potential treatment of multi-drug resistant cancer cells. The dual-delivery system could also apply to diabetes and other conditions requiring a variety of therapeutic approaches.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Nikolaos Zacharias, MD 1 Medical Center Dr, Vascular Surgery, Lebanon, NH 03756-1000 Ph: (603) 650-8677 | Nikolaos Zacharias, MD 1 Medical Center Dr, Vascular Surgery, Lebanon, NH 03756-1000 Ph: (603) 650-8677 |
News Archive
Again, the Venza Group generated a positive impact on the lives of Georgia's foster and adoption families by sponsoring their 2nd Annual Charity Wine-Tasting Event. The crowd sipped and sampled in assistance of Supporting Adoption and Foster Families Together (SAFFT), a newly established organization that declares the following belief: BUILDING and MAINTAINING a supportive foundation for all caregivers improves the overall lives of children in care.
The drug was rejected in a 10-6 vote the first time it came before a Food and Drug Administration (FDA) advisory panel, in 2010, due to safety concerns. However when the medication returned for another review in February, the advisory committee gave it near-unanimous approval (20-2). Because the FDA often follows the advisory panel's advice, Qnexa is likely to get FDA approval, probably by mid-April.
The widespread adoption of the use of drug-releasing coronary artery stents into routine practice is associated with a decrease in the need for repeat procedures to unblock coronary arteries and also do not appear to increase the risk of death, compared to bare-metal stents, according to a study in the June 25 issue of JAMA, the Journal of the American Medical Association
Alex Dopico, MD, PhD, professor and Van Vleet Chair of Excellence in the Department of Pharmacology, Addiction Science, and Toxicology, and Anna Bukiya, PhD, associate professor in the Department of Pharmacology, Addiction Science, and Toxicology, have been awarded $2.4 million from the National Heart, Lung, and Blood Institute to explore how cholesterol interacts with the mechanisms that modulate blood vessel function in the brain.
The National Science Foundation recently funded research aimed at developing an engineered protein-lipid system that simultaneously delivers genes and drugs for the potential treatment of multi-drug resistant cancer cells. The dual-delivery system could also apply to diabetes and other conditions requiring a variety of therapeutic approaches.
› Verified 7 days ago
Juliana Castellano, MD, PHD Surgery Medicare: Accepting Medicare Assignments Practice Location: One Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-8693 | |
Gina Lynn Adrales, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-8113 Fax: 603-650-8030 | |
Astrid Gleaton, M.D. Surgery Medicare: Medicare Enrolled Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-5000 | |
Stefanie Sueda, Surgery Medicare: Medicare Enrolled Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-5000 | |
Dr. James C Cooros, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-8050 | |
Dr. David H Stone, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Dhmc Department Of Surgery, Lebanon, NH 03756 Phone: 603-650-4682 Fax: 603-650-4973 |